Statute Details
- Title: Human Biomedical Research Regulations 2017
- Type: Subsidiary legislation (SL)
- Authorising Act: Human Biomedical Research Act 2015
- Act Code: HBRA2015-RG1
- Current status: Current version (as at 27 Mar 2026)
- Revised edition: 2025 RevEd (2 June 2025)
- Commencement (as enacted): 1 November 2017 (SL 621/2017)
- Key Parts: Part 1 (Preliminary); Part 2 (Research Institutions); Part 3 (Institutional Review Boards); Part 4 (Miscellaneous)
- Key provisions highlighted in extract: Section 2 (Definitions); Part 2 includes notifications, declarations, adverse event reporting, contamination management, safety/welfare, and incidental findings policy; Part 3 includes IRB appointment/composition, qualifications, conflicts of interest, expedited/exempted review, documentation, and reports; Part 4 includes consent witnessing, appeals, electronic system, false information, and fees
- Related legislation (examples from metadata): Human Biomedical Research Act 2015; Allied Health Professions Act 2011; Dental Registration Act 1999; Midwives Act 1999; Pharmacists Registration Act 2007; Traditional Chinese Medicine Practitioners Act 2000; Nurses and Midwives Act 1999
What Is This Legislation About?
The Human Biomedical Research Regulations 2017 (“HBRA Regulations”) are subsidiary rules made under the Human Biomedical Research Act 2015. In plain language, they operationalise how human biomedical research must be conducted and governed in Singapore—especially the administrative and compliance duties of research institutions and the decision-making processes of Institutional Review Boards (IRBs).
While the Human Biomedical Research Act 2015 sets the overarching legal framework (including licensing/authorisation concepts and core duties), the Regulations provide the “how”: they specify what research institutions must notify, what declarations must be made, how serious adverse events must be reported, and what policies must exist (for example, on incidental findings). They also set out the governance mechanics for IRBs, including membership requirements, conflict-of-interest safeguards, and procedural expectations for review outcomes.
Practically, the Regulations are designed to protect research subjects and maintain public trust. They do this by requiring structured oversight, timely reporting of safety issues, and documented decision-making. They also create compliance pathways through electronic systems and defined processes for appeals and fees.
What Are the Key Provisions?
1) Definitions that drive the scope of compliance (Part 1, section 2). The Regulations begin by defining key terms. These definitions are crucial because they determine who must comply and what activities are captured. For example, “healthcare professional” is defined broadly to include medical practitioners, dentists, registered nurses/enrolled nurses/registered midwives, pharmacists, allied health professionals, and certain traditional Chinese medicine practitioners (registered under the Traditional Chinese Medicine Practitioners Act 2000 for prescribed practice). This breadth matters because many IRB and research-subject protections are triggered by the involvement of healthcare professionals.
The Regulations also define “lay person” in a way that excludes individuals who are healthcare professionals, hold equivalent qualifications/registrations abroad corresponding to healthcare professional qualifications, or who have been involved in research as investigators. This is intended to ensure that at least some IRB members bring non-professional perspectives and can challenge proposals from a public-interest standpoint.
Further, the Regulations define “immediate family relationship” (spouse, child, adopted child, stepchild, brother, sister, parent, step-parent) and “other relationship” (affiliation, participation, financial interest, or competition in the research proposal that may adversely affect impartiality). These definitions are directly relevant to conflict-of-interest rules in Part 3.
2) Research institution duties: notifications, declarations, and safety governance (Part 2). Part 2 sets out compliance obligations for research institutions. The Regulations include requirements for notification by a research institution (section 3) and additional transitional/legacy notification rules for research started before 1 November 2017 (section 4). They also require the appointment of a “principal person in charge” (section 5), and impose duties to update information and particulars when changes occur (section 6).
A core compliance mechanism is the “declaration of compliance” (section 7). Although the extract does not reproduce the declaration text, the Regulations include a “FIRST SCHEDULE” for the declaration of compliance. For practitioners, this means the Regulations are not merely procedural—they require formal attestations, likely tied to the institution’s internal governance and adherence to the Act and Regulations.
Part 2 also contains detailed safety reporting obligations. It defines “serious adverse event” (section 8A) and requires notification of serious adverse events (section 9) and unexpected serious adverse events (section 10). These provisions are significant because they operationalise subject safety monitoring and ensure that regulators and oversight bodies receive timely information about risks that may alter the risk-benefit assessment of ongoing research.
In addition, Part 2 includes provisions on operational continuity and biosafety. Section 10A addresses notification when a research institution’s operations cease. Section 10B addresses management of contamination of human biological material—an important requirement for laboratories and biobanks handling specimens. Section 10C requires policies on safety and welfare of research subjects, and section 10D requires a policy on incidental findings. Incidental findings are findings unrelated to the original research question but potentially relevant to a subject’s health; requiring a policy ensures that institutions pre-plan how such information will be handled ethically and responsibly.
3) IRB governance: composition, conflicts, and review pathways (Part 3). Part 3 provides the framework for Institutional Review Boards. It covers appointment and composition (section 11), qualification of members (section 12), term of office (section 13), notification to the Director-General (section 14), and revocation/disqualification mechanisms (sections 15–17). These provisions ensure that IRBs are properly constituted and that unsuitable members can be removed.
For day-to-day compliance, the conflict-of-interest provisions are particularly important. Section 19 addresses conflicts of interest, and the definitions in section 2 (“immediate family relationship” and “other relationship”) are designed to support this. In practice, IRB members must be able to demonstrate impartiality and independence when reviewing proposals, especially where they have personal, financial, or professional ties to investigators or the research proposal.
Part 3 also includes procedural review mechanisms. Section 20 provides for “expedited review” (a faster process for certain categories of research that meet defined criteria), while section 21 provides for “exempted review” (research that may be exempt from full review under specified conditions). These pathways are important for efficiency, but they still require appropriate documentation and safeguards.
Documentation and communications are addressed in section 22. Section 23 requires written reasons to be provided to a second institutional review board—this suggests a structured escalation or reconsideration mechanism where another IRB must review or respond to the initial decision. Section 24 requires reports to the research institution, ensuring that institutional leadership receives formal outcomes and rationales.
4) Miscellaneous compliance: consent witnessing, appeals, electronic systems, and penalties (Part 4). Part 4 includes practical operational rules. Section 25 requires a “witness to appropriate consent,” which is a key ethical and legal safeguard ensuring that consent processes are properly observed and documented. Section 27 sets out the procedure for appeal to the Minister, providing a formal route for challenging decisions within the regulatory framework.
Section 28 introduces an “electronic system,” indicating that notifications, submissions, or communications may be required or facilitated through an online platform. For practitioners, this is a compliance-critical point: failure to use the correct system or to meet electronic submission requirements can create procedural non-compliance even where substantive ethics are sound.
Section 29 addresses false information, signalling that misstatements or omissions in notifications or declarations can attract enforcement consequences. Section 30 provides for fees, which is relevant to budgeting and to understanding the cost structure for regulatory processes.
How Is This Legislation Structured?
The HBRA Regulations are organised into four Parts:
Part 1 (Preliminary) contains citation and definitions (including “healthcare professional,” “lay person,” “immediate family relationship,” “other relationship,” “scientific person,” and “relevant website” for the electronic system).
Part 2 (Research Institutions) sets out institutional duties: notifications, principal person in charge, declaration of compliance, serious adverse event reporting, unexpected serious adverse event reporting, cessation notification, contamination management, safety and welfare policies, and incidental findings policies.
Part 3 (Institutional Review Boards) governs IRB establishment and operation: appointment/composition, member qualifications, terms, notifications to the Director-General, disqualification and revocation, meetings/quorum, conflicts of interest, expedited and exempted review, documentation, written reasons for second IRB review, and reporting back to the institution.
Part 4 (Miscellaneous) includes consent witnessing, appeal procedures, electronic system requirements, false information, and fees.
The Regulations also include Schedules, including a “FIRST SCHEDULE” for the declaration of compliance and a “SECOND SCHEDULE” for legislative history.
Who Does This Legislation Apply To?
The HBRA Regulations apply primarily to research institutions conducting human biomedical research and to Institutional Review Boards reviewing research proposals. They also indirectly affect investigators, because institutional duties (notifications, safety policies, adverse event reporting, and consent witnessing) require investigators to provide information and comply with institutional processes.
The scope is shaped by the definitions in Part 1. For example, the definition of “healthcare professional” is broad and includes multiple regulated professions and certain traditional Chinese medicine practitioners. This matters because IRB composition and consent-related obligations often depend on whether healthcare professionals are involved, and because “lay person” status is defined by exclusion criteria tied to healthcare professional qualifications and research involvement.
Why Is This Legislation Important?
The HBRA Regulations are important because they translate ethical and safety principles into enforceable administrative requirements. For practitioners—research compliance officers, IRB secretariats, clinical trial managers, and legal counsel—the Regulations provide the compliance checklist needed to manage risk: from initial notifications and declarations, to ongoing safety reporting and incident management, to IRB governance and conflict-of-interest controls.
From an enforcement perspective, the Regulations create multiple points of potential non-compliance: late or missing adverse event notifications, inadequate policies on safety/welfare or incidental findings, improper IRB composition, failure to manage conflicts, or submission of false information. The inclusion of an electronic system further increases the need for procedural discipline and record-keeping.
Finally, the Regulations support defensibility. Written reasons, documented review processes, and structured escalation (including written reasons to a second IRB) help institutions demonstrate that decisions were made transparently and consistently. This is particularly valuable in disputes, audits, and appeals to the Minister.
Related Legislation
- Human Biomedical Research Act 2015 (authorising Act; including section 63 referenced in the legislation page)
- Allied Health Professions Act 2011
- Dental Registration Act 1999
- Nurses and Midwives Act 1999 (as referenced in the definition of “healthcare professional”)
- Midwives Act 1999 (listed in metadata)
- Pharmacists Registration Act 2007
- Traditional Chinese Medicine Practitioners Act 2000
Source Documents
This article provides an overview of the Human Biomedical Research Regulations 2017 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.